CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices

Cardiora Pty. Ltd.1 site in 1 country6 target enrollmentMarch 6, 2018

ConditionsRight Heart Failure Left Ventricular Assist Device

InterventionsCRD-102

DrugsCRD-102

Overview

Phase: Phase 1
Intervention: CRD-102
Conditions: Right Heart Failure
Sponsor: Cardiora Pty. Ltd.
Enrollment: 6
Locations: 1
Primary Endpoint: Safety: Subject incidence of adverse events
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a Phase 1b/IIa, single centre, non-randomised open-label uncontrolled study to assess safety, effect and PK of oral CRD-102 in patients with RHF associated with the presence of an LVAD.

Detailed Description

The study will be conducted over a 40 day time period inclusive of screening and follow up time periods. Eligible subjects will receive oral CRD-102 for 14 days.

Registry

clinicaltrials.gov

Start Date

March 6, 2018

End Date

May 30, 2019

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Cardiora Pty. Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients are enrolled only if they met the following criteria.
•Males and females aged 18-85 years inclusive
•Have received a LVAD (HeartWare HVAD, HeartMate II) at least 30 days prior to screening.
•Stable LVAD patients with evidence of ongoing right heart failure as evidenced by raised right atrial pressure indicated by JVP \>6cm OR measured right atrial pressure ≥12mmHg within the 3 months prior to or at Baseline OR dilated IVC on echocardiography PLUS all of the following;
•ongoing diuretic therapy;
•echocardiography in the 3 months prior to or at Baseline showing at least mild impairment in overall RV systolic function by visual assessment together with a TAPSE \< 14mm.
•Able to give written informed consent and agree to adhere to all protocol requirements.
•All patients will be required to have an implanted cardiaoverter defibrillator. (ICD)

Exclusion Criteria

•Hemodynamically unstable patients.
•Hypotension (MAP\<60 or systolic BP \<90 mmHg) at Screening or Baseline
•Hypertension (MAP\>95 or systolic BP \>130 mmHg) at Screening or Baseline
•Ventricular tachycardia or ventricular fibrillation in the past 30 days or poorly controlled atrial fibrillation (ventricular rate \>120 bpm)
•Concurrent participation in another investigational device study or prior participation in which a device was implanted and remains in place
•Receipt of any investigational research agent within 30 days or 5 half-lives (whichever is longer) prior to Baseline.
•Current treatment with intravenous inotropes or levosimendan, or treatment within the 2 weeks prior to Screening
•Significant renal (eGFR\<25 ml/min/1.73 sq m) or hepatic (bilirubin \>3mg/dL) impairment or anemia (Hb \<90g/dL) at Screening or Baseline.
•Expected heart transplantation within the study period.
•History of allergic reaction to milrinone or any excipients in the study drug.